Citigroup Issues Positive Forecast for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its price target upped by research analysts at Citigroup from $150.00 to $170.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical instruments supplier’s stock. Citigroup‘s price objective suggests a potential upside of 8.91% from the company’s current price.

Other analysts have also issued reports about the stock. Stifel Nicolaus lowered their price objective on shares of Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Royal Bank Of Canada lifted their price objective on Insulet from $160.00 to $180.00 and gave the company an “outperform” rating in a research report on Thursday. Jefferies Financial Group reiterated a “buy” rating and set a $200.00 target price on shares of Insulet in a report on Wednesday. Oppenheimer lowered Insulet from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Finally, Raymond James Financial restated an “outperform” rating and issued a $180.00 target price on shares of Insulet in a research note on Thursday, August 6th. Thirteen equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Insulet has a consensus rating of “Hold” and an average target price of $190.80.

Insulet Trading Down 5.4%

Shares of Insulet stock traded down $8.93 during midday trading on Thursday, reaching $156.09. 1,319,076 shares of the company’s stock traded hands, compared to its average volume of 1,397,986. The stock has a 50 day moving average of $141.65 and a 200-day moving average of $178.00. Insulet has a 12 month low of $126.40 and a 12 month high of $354.88. The company has a market cap of $10.82 billion, a PE ratio of 29.18, a price-to-earnings-growth ratio of 1.22 and a beta of 1.06. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.59 by $0.40. The business had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm’s revenue for the quarter was up 19.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.24 earnings per share. As a group, equities analysts expect that Insulet will post 6.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Insulet

Several large investors have recently made changes to their positions in PODD. BlackRock Inc. bought a new stake in shares of Insulet during the 2nd quarter valued at $1,018,582,000. Arrowstreet Capital Limited Partnership boosted its holdings in Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after buying an additional 1,011,369 shares during the period. Man Group plc purchased a new stake in Insulet in the 2nd quarter worth $78,746,000. Bank of America Corp DE purchased a new stake in Insulet in the 2nd quarter worth $64,921,000. Finally, Bank of New York Mellon Corp purchased a new stake in Insulet in the 2nd quarter worth $60,615,000.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported Q3 adjusted EPS of $1.99, ahead of the $1.59 consensus, and revenue of $842 million, up 19.2% year over year and above estimates. Read article
• Positive Sentiment: The company announced a $1 billion share-repurchase authorization, which could support shareholder returns. Read article
• Positive Sentiment: Several firms raised their price targets: RBC to $180 and Bernstein to $200, both with outperform ratings; Leerink Partners raised its target to $167 while maintaining market perform. RBC article
• Negative Sentiment: Management expects slower growth in 2027 and anticipates competitors taking some share from its Omnipod product. That outlook may be overshadowing the Q3 beat and prompting caution about future growth. Read article

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.